• Press Release

LPixel Receives Pre-Market Certification in Japan for EIRL basic

Tokyo, Japan – October 25, 2018 – LPixel Inc., a leader in image analysis and processing technology in life science and medical research, announced today that it has secured the Japanese Pre-Market Certification, in accordance with the Pharmaceutical Affairs Law (PAL), for EIRL basic (certification number: 230AGBZX00107000). EIRL basic is LPixel’s medical image analysis software equipped with measurement functionalities for brain MRI. LPixel plans to prepare for the expansion of the nationwide deployment of EIRL basic in the following year.
About EIRL
EIRL is the collective name given to LPixel’s AI medical image diagnostic support technology. LPixel aims to provide solutions that enable a faster and more accurate diagnosis by implementing its unique algorithms to analyze medical big data, such as brain and breast MRI, chest X-rays, colonoscopy and pathology.
About LPixel
LPixel is a leader in advanced image analysis and processing technology encompassing the life science field. Founded in March 2014, LPixel is dedicated to offering research facilities top-tier image analysis technologies and medical diagnosis technologies, both of which adopt advanced AI technology. The company is currently working in collaboration with the University of Tokyo Hospital, the National Cancer Center Japan and other research institutions to further the development of its AI-based medical diagnosis technology. For more information, please visit
Contact Details
LPixel Inc.


Cutting-Edge Technologies that Lead Future Medical Diagnosis
EIRL analyzes a wide range of medical data to provide an accurate and efficient diagnosis. EIRL aims to be the closest partner to all doctors, and serve as another powerful set of eyes to provide top quality medical care.
AI Accelerating
Phase R&D
IMACEL, an image analysis AI, helps to solve various issues in the drug discovery process.
Life science and AI experts support successful AI implementation.



Alphabetical listing


A Third Career Option for Researchers